BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cui G. The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses. Front Oncol 2021;11:573547. [PMID: 33763344 DOI: 10.3389/fonc.2021.573547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Xie P, Zheng H, Chen H, Wei K, Pan X, Xu Q, Wang Y, Tang C, Gevaert O, Meng X. Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival. BMC Cancer 2021;21:1246. [PMID: 34798858 DOI: 10.1186/s12885-021-08944-9] [Reference Citation Analysis]
2 Nie C, Lv H, Liu Y, Chen B, Xu W, Wang J, Chen X. Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study. Front Oncol 2021;11:741865. [PMID: 34631579 DOI: 10.3389/fonc.2021.741865] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Gomar M, Najafi M, Aghili M, Cozzi S, Jahanbakhshi A. Durable complete response to pembrolizumab in microsatellite stable colorectal cancer. Daru 2021. [PMID: 34254265 DOI: 10.1007/s40199-021-00404-w] [Reference Citation Analysis]
4 Salewski I, Henne J, Engster L, Schneider B, Lemcke H, Skorska A, Berlin P, Henze L, Junghanss C, Maletzki C. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors. Int J Mol Sci 2021;22:5990. [PMID: 34206051 DOI: 10.3390/ijms22115990] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]